IL141220A0 - Conjugates of peg-urate oxidase and use thereof - Google Patents
Conjugates of peg-urate oxidase and use thereofInfo
- Publication number
- IL141220A0 IL141220A0 IL14122099A IL14122099A IL141220A0 IL 141220 A0 IL141220 A0 IL 141220A0 IL 14122099 A IL14122099 A IL 14122099A IL 14122099 A IL14122099 A IL 14122099A IL 141220 A0 IL141220 A0 IL 141220A0
- Authority
- IL
- Israel
- Prior art keywords
- conjugates
- peg
- urate oxidase
- urate
- oxidase
- Prior art date
Links
- 229940005267 urate oxidase Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13039298A | 1998-08-06 | 1998-08-06 | |
| PCT/US1999/017514 WO2000007629A2 (en) | 1998-08-06 | 1999-08-02 | Peg-urate oxidase conjugates and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL141220A0 true IL141220A0 (en) | 2002-03-10 |
Family
ID=22444494
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14122099A IL141220A0 (en) | 1998-08-06 | 1999-08-02 | Conjugates of peg-urate oxidase and use thereof |
| IL141220A IL141220A (en) | 1998-08-06 | 2001-02-01 | PEG couplings - urate oxidase and their use |
| IL183948A IL183948A (en) | 1998-08-06 | 2007-06-14 | Peg-urate oxidase conjugates and use thereof |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL141220A IL141220A (en) | 1998-08-06 | 2001-02-01 | PEG couplings - urate oxidase and their use |
| IL183948A IL183948A (en) | 1998-08-06 | 2007-06-14 | Peg-urate oxidase conjugates and use thereof |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1100542B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5183836B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR100614212B1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU770014B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BRPI9912974B8 (cg-RX-API-DMAC7.html) |
| CZ (1) | CZ303751B6 (cg-RX-API-DMAC7.html) |
| HU (2) | HU226294B1 (cg-RX-API-DMAC7.html) |
| IL (3) | IL141220A0 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ509595A (cg-RX-API-DMAC7.html) |
| PL (2) | PL220873B1 (cg-RX-API-DMAC7.html) |
| RU (3) | RU2246318C2 (cg-RX-API-DMAC7.html) |
| TW (1) | TW570981B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000007629A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2158923B1 (en) | 1998-08-06 | 2013-02-27 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
| BRPI9912974B8 (pt) * | 1998-08-06 | 2021-05-25 | Univ Duke | conjugados de peg-urato oxidase e seu uso |
| US6783965B1 (en) * | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| NZ509633A (en) | 1998-08-06 | 2003-04-29 | Univ Duke | A recombinant chimeric PEG-uricase with a long circulatory life and reduced immunogenicity |
| AU2006203252B8 (en) * | 2000-02-10 | 2009-06-18 | Duke University | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| CA2404737C (en) | 2000-04-03 | 2010-06-29 | Santen Pharmaceutical Co., Ltd. | Drug delivering substance containing polyalkylene glycol and phospholipid covalently bonded to drug |
| AU2001268734A1 (en) | 2000-06-28 | 2002-01-08 | Merck & Co., Inc. | Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease |
| CA2450985A1 (en) | 2001-06-28 | 2003-01-09 | Mountain View Pharmaceuticals, Inc. | Polymer stabilized proteinases |
| US6913915B2 (en) * | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| US20040062748A1 (en) | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| NZ543935A (en) | 2003-05-12 | 2008-06-30 | Affymax Inc | Peptides that bind to the erythropoietin receptor |
| EA010015B1 (ru) | 2003-05-12 | 2008-06-30 | Афимакс, Инк. | Новый разделительный фрагмент (спейсер) для модифицированных полиэтиленгликолем соединений на основе пептидов |
| WO2006005058A2 (en) * | 2004-06-30 | 2006-01-12 | Nektar Therapeutics Al, Corporation | Polymer-factor ix moiety conjugates |
| SG2014009484A (en) * | 2005-04-11 | 2014-05-29 | Savient Pharmaceuticals Inc | A variant form of urate oxidase and use thereof |
| US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| NZ562292A (en) | 2005-04-11 | 2009-11-27 | Savient Pharmaceuticals Inc | Variant forms of urate oxidase and use thereof |
| WO2006121995A2 (en) | 2005-05-09 | 2006-11-16 | Tap Pharmaceutical Products, Inc. | Methods for treating nephrolithiasis |
| US7550433B2 (en) | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| JP5033177B2 (ja) * | 2006-04-12 | 2012-09-26 | サビエント ファーマセウティカルズ インク． | 陽イオン界面活性剤によるタンパク質の精製 |
| JP4890132B2 (ja) * | 2006-07-20 | 2012-03-07 | 東洋紡績株式会社 | ウリカーゼの比活性を向上させる方法、および比活性の向上した改変型ウリカーゼ |
| RU2382048C1 (ru) * | 2008-12-25 | 2010-02-20 | Общество С Ограниченной Ответственностью "Фармапарк" | Лекарственное средство на основе модифицированного интерферона альфа с пролонгированным терапевтическим действием |
| NZ597089A (en) | 2009-06-25 | 2014-05-30 | Savient Pharmaceuticals Inc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| AU2011299153B2 (en) | 2010-09-10 | 2014-10-30 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for concomitant treatment of theophylline and febuxostat |
| CN102634492B (zh) | 2011-02-14 | 2015-06-10 | 重庆富进生物医药有限公司 | 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用 |
| EP2833883A4 (en) | 2012-04-06 | 2015-12-23 | Indus Pharmaceuticals Inc | NOVEL COMPOSITIONS OF COMBINATIONS OF NONCOVALENT DNA BINDER AND CANCER-INHIBITING AND / OR INFLAMMATORY ACTIVE SUBSTANCES AND THEIR USE IN THE TREATMENT OF ILLNESSES |
| MX380164B (es) | 2013-05-03 | 2025-03-12 | Selecta Biosciences Inc | Uso de una macromolécula terapéutica y una composición que comprende nanoportadores sintéticos que se unen a inmunosupresores para reducir la hipersensibilidad tipo i y tipo iv en un sujeto. |
| CA2984926A1 (en) | 2015-05-15 | 2016-11-24 | Medimmune, Llc | Improved uricase sequences and methods of treatment |
| CN105412942B (zh) * | 2015-12-23 | 2019-02-26 | 沈阳三生制药有限责任公司 | 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂 |
| WO2018089808A1 (en) | 2016-11-11 | 2018-05-17 | Horizon Pharma Rheumatology Llc | Combination therapies of prednisone and uricase molecules and uses thereof |
| US20200237881A1 (en) | 2019-01-30 | 2020-07-30 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| WO2018169811A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| CN112980808B (zh) * | 2019-12-12 | 2024-10-29 | 深圳迈瑞生物医疗电子股份有限公司 | 尿酸酶、及其制备方法和用途 |
| EP4240423A1 (en) | 2020-11-03 | 2023-09-13 | Protalix Ltd. | Modified uricase and uses thereof |
| CN114438048B (zh) * | 2020-11-05 | 2024-10-22 | 重庆派金生物科技有限公司 | 尿酸氧化酶制剂及其应用 |
| CN114438047B (zh) * | 2020-11-05 | 2024-11-22 | 重庆派金生物科技有限公司 | 制备聚乙二醇修饰的尿酸氧化酶的方法 |
| JPWO2022172343A1 (cg-RX-API-DMAC7.html) | 2021-02-10 | 2022-08-18 | ||
| CN114181917B (zh) * | 2022-02-14 | 2022-06-03 | 潍坊华卓生物科技有限公司 | 一种改造尿酸酶、基因序列、制备方法及应用 |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR6301M (cg-RX-API-DMAC7.html) * | 1967-03-29 | 1968-09-09 | ||
| US3616231A (en) * | 1968-11-14 | 1971-10-26 | Boehringer Mannheim Gmbh | Process for the production of uricase |
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6031472B2 (ja) * | 1978-12-14 | 1985-07-22 | 協和醗酵工業株式会社 | 酸性ウリカ−ゼ |
| JPS55135590A (en) * | 1979-04-05 | 1980-10-22 | Mihama Hisaharu | Modified asparaginase and uricase and their preparation |
| JPS57192435A (en) * | 1981-05-20 | 1982-11-26 | Toyobo Co Ltd | Modified polypeptide |
| JPS6255079A (ja) * | 1986-04-23 | 1987-03-10 | Mihama Hisaharu | 修飾ウリカ−ゼ |
| NZ234453A (en) * | 1989-07-13 | 1993-01-27 | Sanofi Sa | Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith |
| BRPI9912974B8 (pt) * | 1998-08-06 | 2021-05-25 | Univ Duke | conjugados de peg-urato oxidase e seu uso |
| NZ509633A (en) * | 1998-08-06 | 2003-04-29 | Univ Duke | A recombinant chimeric PEG-uricase with a long circulatory life and reduced immunogenicity |
| US6783965B1 (en) * | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
-
1999
- 1999-08-02 BR BRPI9912974A patent/BRPI9912974B8/pt not_active IP Right Cessation
- 1999-08-02 PL PL383331A patent/PL220873B1/pl unknown
- 1999-08-02 CZ CZ20010317A patent/CZ303751B6/cs not_active IP Right Cessation
- 1999-08-02 EP EP99937745A patent/EP1100542B1/en not_active Expired - Lifetime
- 1999-08-02 IL IL14122099A patent/IL141220A0/xx active IP Right Grant
- 1999-08-02 JP JP2000563311A patent/JP5183836B2/ja not_active Expired - Fee Related
- 1999-08-02 HU HU0103003A patent/HU226294B1/hu not_active IP Right Cessation
- 1999-08-02 WO PCT/US1999/017514 patent/WO2000007629A2/en not_active Ceased
- 1999-08-02 PL PL380583A patent/PL202799B1/pl unknown
- 1999-08-02 KR KR1020047014428A patent/KR100614212B1/ko not_active Expired - Fee Related
- 1999-08-02 RU RU2001103144/15A patent/RU2246318C2/ru not_active IP Right Cessation
- 1999-08-02 NZ NZ509595A patent/NZ509595A/xx not_active IP Right Cessation
- 1999-08-02 BR BRPI9917760A patent/BRPI9917760B8/pt not_active IP Right Cessation
- 1999-08-02 AU AU52515/99A patent/AU770014B2/en not_active Ceased
- 1999-08-02 KR KR10-2001-7001569A patent/KR100488848B1/ko not_active Expired - Fee Related
- 1999-08-02 RU RU2004104953/15A patent/RU2278680C2/ru not_active IP Right Cessation
- 1999-08-02 HU HU0800112A patent/HU228916B1/hu not_active IP Right Cessation
- 1999-08-05 TW TW088113406A patent/TW570981B/zh not_active IP Right Cessation
-
2001
- 2001-02-01 IL IL141220A patent/IL141220A/en not_active IP Right Cessation
-
2006
- 2006-03-09 RU RU2006107111/15A patent/RU2349341C2/ru not_active IP Right Cessation
-
2007
- 2007-06-14 IL IL183948A patent/IL183948A/en not_active IP Right Cessation
-
2009
- 2009-07-24 JP JP2009173148A patent/JP5290901B2/ja not_active Expired - Fee Related
-
2012
- 2012-11-12 JP JP2012248770A patent/JP5291235B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL183948A0 (en) | Conjugates of peg-urate oxidase and use thereof | |
| IL128869A0 (en) | Pyrozolopyrimidines and pyrazolotriazines | |
| AU7718898A (en) | Txu-7-pap immunotoxin and use thereof | |
| AU8967998A (en) | Antibiotic-ligand conjugates and methods of use thereof | |
| GB9813271D0 (en) | Composition and use | |
| ZA200101933B (en) | Novel composition and use | |
| HUP0105411A3 (en) | Palladium-substituted bacteriochlorophyll derivatives and use thereof | |
| PL332616A1 (en) | Hydoxymethylhexanones as odorising and savourising agents | |
| EG22491A (en) | Rest-breaking composition and use thereof | |
| GB9807586D0 (en) | Enzymes and their use | |
| GB0318113D0 (en) | ›-Secretase enzyme compositions and methods | |
| AU6084598A (en) | Antibiotic-ligand conjugates and methods of use thereof | |
| IL120481A0 (en) | Combined enzyme composition and its use | |
| GB9911606D0 (en) | Composition and use | |
| GB9805172D0 (en) | Composition and use | |
| GB9722392D0 (en) | Composition and use | |
| GB9714382D0 (en) | Enzymes and their use | |
| GB9824869D0 (en) | Novel composition and use | |
| GB9824866D0 (en) | Novel composition and use | |
| GB9824867D0 (en) | Novel composition and use | |
| GB9826250D0 (en) | Novel composition and use | |
| GB9824870D0 (en) | Novel composition and use | |
| GB9910410D0 (en) | Enzymes and uses thereof | |
| EG24062A (en) | Novel composition and use | |
| GB9816014D0 (en) | Piperidinecarboxamides and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |